Abstract
7574 Background: Cytotoxic T lymphocyte associated antigen 4 (CTLA4), programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are key components of immune checkpoints and the most attractive targets in immunotherapy for cancer. These antigens are abundant in tumor samples, however their distribution and clinical value in liquid biopsy (such as blood) of small-cell lung cancer (SCLC) patients remains unclear. Methods: 60 healthy and 230 chemotherapy-naive patients with SCLC were recruited. Venous blood samples were collected prior to chemotherapy (baseline) and after the second cycle of chemotherapy (2nd cycle), and flow cytometry was used to analyze the level of CTLA4, PD-1 or PD-L1 with or without CD3, CD4, CD8 or CD25. Immunohistochemistry was used to detect PD-L1 expression in SCLC cell line H446. Results: Cells of CTLA4+, CD3+CTLA4+ and CD4+CTLA4+ in SCLC were (1.06±1.51)%, (4.12±5.30)% and (3.95±2.80)%, respectively and PD-1+, CD3+PD-1+, and CD4+PD-1+ were (7.96±3.38)%, (25.86±8.49) % and (20...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.